Yiping Chen1, Lixin Jiang2, Margaret Smith3, Hongchao Pan3, Rory Collins3, Richard Peto3, Zhengming Chen1. 1. Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; China Oxford Centre for International Health Research, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, PR China. 2. China Oxford Centre for International Health Research, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, PR China. 3. Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Abstract
OBJECTIVE: To assess the sex difference in hospital mortality following ST elevation myocardial infarction (STEMI) in China. DESIGN: Observational study of patients enrolled into a large trial, adjusting for age, presenting characteristics and hospital treatments using logistic regression. SETTINGS: 1250 hospitals in China during 1999-2005. PATIENTS: 42 683 STEMI patients, including 31 309 men and 11 374 women. INTERVENTION: In the original trial, all patients received 162 mg of aspirin plus 75 mg of clopidogrel daily or matching placebo and metoprolol (15 mg intravenous then 200 mg oral daily) or matching placebo. All other aspects of patients' treatments were at the discretion of responsible doctors. MAJOR OUTCOMES: Hospital mortality from any cause during the scheduled trial treatment period (ie, up to 4 weeks in hospital). RESULTS: Overall, 8% of the patients died in hospital, with the crude hospital mortality being twice as high in women as in men (12.6% vs 6.3%). After adjusting for age, the sex difference in hospital mortality attenuated but remained highly significant (OR 1.54; 95% CI 1.43 to 1.66). Further adjustment for other baseline characteristics and for the treatments given in hospital had little effect on the sex difference in hospital mortality (OR 1.50, 95% CI 1.38 to 1.62). The difference in hospital mortality was greater at a younger age, with the adjusted ORs being 2.14, 1.70, 1.48 and 1.18, respectively, for ages <55, 55-64, 65-74 and ≥75 years (p=0.0001 for trend). CONCLUSION: Compared with men of the same age, women had approximately a 50% higher mortality following hospital admission for STEMI, with a particularly higher excess risk at age <55 years.
OBJECTIVE: To assess the sex difference in hospital mortality following ST elevation myocardial infarction (STEMI) in China. DESIGN: Observational study of patients enrolled into a large trial, adjusting for age, presenting characteristics and hospital treatments using logistic regression. SETTINGS: 1250 hospitals in China during 1999-2005. PATIENTS: 42 683 STEMI patients, including 31 309 men and 11 374 women. INTERVENTION: In the original trial, all patients received 162 mg of aspirin plus 75 mg of clopidogrel daily or matching placebo and metoprolol (15 mg intravenous then 200 mg oral daily) or matching placebo. All other aspects of patients' treatments were at the discretion of responsible doctors. MAJOR OUTCOMES: Hospital mortality from any cause during the scheduled trial treatment period (ie, up to 4 weeks in hospital). RESULTS: Overall, 8% of the patients died in hospital, with the crude hospital mortality being twice as high in women as in men (12.6% vs 6.3%). After adjusting for age, the sex difference in hospital mortality attenuated but remained highly significant (OR 1.54; 95% CI 1.43 to 1.66). Further adjustment for other baseline characteristics and for the treatments given in hospital had little effect on the sex difference in hospital mortality (OR 1.50, 95% CI 1.38 to 1.62). The difference in hospital mortality was greater at a younger age, with the adjusted ORs being 2.14, 1.70, 1.48 and 1.18, respectively, for ages <55, 55-64, 65-74 and ≥75 years (p=0.0001 for trend). CONCLUSION: Compared with men of the same age, women had approximately a 50% higher mortality following hospital admission for STEMI, with a particularly higher excess risk at age <55 years.
Authors: Jeffrey S Berger; Laine Elliott; Dianne Gallup; Matthew Roe; Christopher B Granger; Paul W Armstrong; R John Simes; Harvey D White; Frans Van de Werf; Eric J Topol; Judith S Hochman; L Kristin Newby; Robert A Harrington; Robert M Califf; Richard C Becker; Pamela S Douglas Journal: JAMA Date: 2009-08-26 Impact factor: 56.272
Authors: Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell Journal: N Engl J Med Date: 2007-06-07 Impact factor: 91.245
Authors: Rachel P Dreyer; Christopher Sciria; Erica S Spatz; Basmah Safdar; Gail D'Onofrio; Harlan M Krumholz Journal: Circ Cardiovasc Qual Outcomes Date: 2017-02-22
Authors: Xin Zheng; Rachel P Dreyer; Shuang Hu; Erica S Spatz; Frederick A Masoudi; John A Spertus; Khurram Nasir; Xi Li; Jing Li; Sisi Wang; Harlan M Krumholz; Lixin Jiang Journal: Heart Date: 2014-12-15 Impact factor: 5.994
Authors: Xue Du; Erica S Spatz; Rachel P Dreyer; Shuang Hu; Chaoqun Wu; Xi Li; Jing Li; Sisi Wang; Frederick A Masoudi; John A Spertus; Khurram Nasir; Harlan M Krumholz; Lixin Jiang Journal: J Am Heart Assoc Date: 2016-02-22 Impact factor: 5.501
Authors: Farah Yasmin; Sumeet Kumar; Manjeet Singh; Karan Kumar; Om Parkash; Muhammad Sohaib Asghar; Fareeha Jawed; Tooba Ahmed Kirmani; Muhammad Tanveer Alam Journal: Ann Med Surg (Lond) Date: 2022-04-01